EHA 2019 Farhad Ravandi, MD, PhD

Farhad Ravandi, MD, PhD from the MD Anderson Cancer Center, Houston, USA is commenting on the abstract PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Reference: EHA Library. Bose P. Jun 14, 2019; 266472

Link to abstract: https://library.ehaweb.org/eha/2019/24th/266472/prithviraj.bose.phase.1.2.study.of.ruxolitinib.28rux29.plus.decitabine.28dac29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DPHASE+1%2F2+STUDY+OF+RUXOLITINIB+%28RUX%29+PLUS+DECITABINE+%28DAC%29+IN+PATIENTS+%28PTS%29+WITH+POST-MYELOPROLIFERATIVE+NEOPLASM+ACUTE+MYELOID+LEUKEMIA+%28POST-MPN+AML%29

Related items